Optimal Control of Mixed Immunotherapy and Chemotherapy of Tumors
We investigate a mathematical population model of tumor-immune interactions. The populations involved are tumor cells, specific and non-specific immune cells, and concentrations of therapeutic treatments. We establish the existence of an optimal control for this model and provide necessary conditions for the optimal control triple for simultaneous application of chemotherapy, tumor infiltrating lymphocyte (TIL) therapy, and interleukin-2 (IL-2) treatment. We discuss numerical results for the combination of the chemo-immunotherapy regimens. We find that the qualitative nature of our results indicates that chemotherapy is the dominant intervention with TIL interacting in a complementary fashion with the chemotherapy. However, within the optimal control context, the interleukin-2 treatment does not become activated for the estimated parameter ranges.
© 2008 World Scientific
L.G. de Pillis, K.Renee Fister, W. Gu, Tiffany Head, Kenny Maples, Todd Neal, Kenji Kozai, Anand Murugan, "Optimal Control of Mixed Immunotherapy and Chemotherapy of Tumors", Journal of Biological Systems, Vol. 16, No. 1, 2008, pp. 51-80.